Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Therapeutic Efficacy in Advanced Osteosarcoma Patients In the Clinical Trial of SHR1020-SHR-1210-II-OS (Famitinib and Camrelizumab on Chemo-refractory Osteosarcoma) Based on Genomic Analyses of Tumor Specimens

NCT03997747 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT03997747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03997747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Therapeutic Efficacy in Advanced Osteosarcoma Patients In the Clinical Trial of SHR1020-SHR-1210-II-OS (Famitinib and Camrelizumab on Chemo-refractory Osteosarcoma) Based on Genomic Analyses of Tumor Specimens
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Completed
Start date
August 13, 2019
Completion date
December 1, 2021
Enrollment
38 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

osteosarcoma